Nuvelo Announces Second Quarter 2008 Financial Results and Accomplishments Conference Call
July 10 2008 - 7:30AM
PR Newswire (US)
SAN CARLOS, Calif., July 10 /PRNewswire-FirstCall/ -- Nuvelo, Inc.
(NASDAQ:NUVO) today announced that it will hold a conference call
to discuss its second quarter 2008 financial results and
accomplishments on Wednesday, July 23, 2008, at 4:30 p.m. Eastern
Time (1:30 p.m. Pacific Time). To participate in the conference
call, please dial 866-854-8095 for domestic callers and
706-634-8567 for international callers and reference conference
passcode 52257433. A telephone replay of the conference call will
be available through Saturday, July 26, 2008. To access the replay,
please dial 800-642-1687 for domestic callers and 706-645-9291 for
international callers and reference conference passcode 52257433.
This call is being webcast by Thomson/CCBN. The webcast can be
accessed via Nuvelo's website at http://www.nuvelo.com/ and is also
being distributed through the Thomson StreetEvents Network.
Individual investors can listen to the call at
http://www.earnings.com/, Thomson's individual investor portal,
powered by StreetEvents. Institutional investors can access the
call via Thomson StreetEvents (http://www.streetevents.com/), a
password-protected event management site. About Nuvelo Nuvelo, Inc.
is dedicated to improving the lives of patients through the
discovery, development and commercialization of novel drugs for
acute cardiovascular disease, cancer and other debilitating medical
conditions. Nuvelo's development pipeline includes NU172, a direct
thrombin inhibitor in Phase 1 development for use as a potential
short-acting anticoagulant during medical or surgical procedures;
and preclinical candidate NU206, a Wnt pathway modulator for the
potential treatment of chemotherapy/radiation therapy-induced
mucositis and inflammatory bowel disease. In addition, Nuvelo is
pursuing research programs in leukemia and lymphoma therapeutic
antibodies and Wnt signaling pathway therapeutics to further expand
its pipeline and create additional partnering and licensing
opportunities. Information about Nuvelo is available at our website
at http://www.nuvelo.com/ or by phoning 650-517-8000. This press
release contains "forward-looking statements," which include
statements regarding the timing, progress and anticipated
completion of Nuvelo's clinical stage and research programs and the
potential benefits that patients may experience from the use of our
clinical stage compounds, which statements are hereby identified as
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
Such statements are based on our management's current expectations
and involve risks and uncertainties. Actual results and performance
could differ materially from those projected in the forward-
looking statements as a result of many factors, including, without
limitation, uncertainties relating to drug discovery and the
regulatory approval process; clinical development processes;
enrollment rates for patients in our clinical trials; changes in
relationships with strategic partners and dependence upon strategic
partners for the performance of critical activities under
collaborative agreements; and the impact of competitive products
and technological changes. These and other factors are identified
and described in more detail in Nuvelo's filings with the SEC,
including without limitation Nuvelo's quarterly report on Form 10-Q
for the quarter ended March 31, 2008 and subsequent filings. We
disclaim any intent or obligation to update these forward-looking
statements. DATASOURCE: Nuvelo, Inc. CONTACT: Lee Bendekgey, SVP
and Chief Financial Officer of Nuvelo, Inc., +1-650-517-8358, ; or
Nicole Foderaro of WeissComm Partners, +1-415-946-1058, , for
Nuvelo, Inc. Web site: http://www.nuvelo.com/
Copyright
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Holdco Nuvo Group DG (NASDAQ:NUVO)
Historical Stock Chart
From Jul 2023 to Jul 2024